Gene Editing Stocks
Track and analyze companies pioneering CRISPR and advanced genetic engineering technologies
# | Company | Price | Market Cap | Gene Tech Angle | Tags |
---|---|---|---|---|---|
1 |
![]() Vertex Pharmaceuticals Incorporated
VRTX
|
$475.58 | $122.48B | CRISPR-based type 1 diabetes treatment | CRISPR Diabetes Partnership |
2 |
![]() Alnylam Pharmaceuticals, Inc.
ALNY
|
$273.815 | $35.32B | RNAi therapeutic platform | RNAi Platform Rare Disease |
3 |
![]() Moderna, Inc.
MRNA
|
$33.28 | $12.81B | mRNA therapeutic platform | mRNA Platform Vaccines |
4 |
![]() Sarepta Therapeutics, Inc.
SRPT
|
$110.79 | $10.58B | Gene therapy for muscular disorders | AAV DMD Muscle |
5 |
![]() Signify Health, Inc.
SGFY
|
$30.49 | $8.93B | Gene therapy manufacturing platform | Manufacturing Platform Services |
6 |
![]() CRISPR Therapeutics AG
CRSP
|
$40.52 | $3.46B | Pioneer in CRISPR-Cas9 gene editing | CRISPR Ex-Vivo Sickle Cell |
7 |
![]() Beam Therapeutics Inc.
BEAM
|
$27.45 | $2.27B | Base editing technology platform | Base Editing Precision Platform |
8 |
![]() Rocket Pharmaceuticals, Inc.
RCKT
|
$10.4704 | $1.11B | Lentiviral gene therapy platform | Lentiviral Rare Disease Platform |
9 |
![]() Intellia Therapeutics, Inc.
NTLA
|
$10.01 | $1.02B | In vivo CRISPR therapeutic applications | CRISPR In-Vivo Liver |
10 |
![]() Ginkgo Bioworks Holdings, Inc.
DNA
|
$13.87 | $797.78M | Synthetic biology and gene writing | Synthetic Bio Platform Writing |
11 |
![]() Sana Biotechnology, Inc.
SANA
|
$3.1385 | $700.73M | In vivo cell and gene therapy | Cell Therapy Platform Research |
12 |
![]() Verve Therapeutics, Inc.
VERV
|
$8.26 | $699.32M | Base editing for cardiovascular disease | Base Editing Cardiovascular Lipids |
13 |
![]() MeiraGTx Holdings plc
MGTX
|
$6.7501 | $527.54M | Gene therapy for ocular diseases | AAV Ocular Manufacturing |
14 |
![]() Precigen, Inc.
PGEN
|
$1.64 | $480.31M | UltraCAR-T and gene therapy platform | CAR-T Platform Oncology |
15 |
![]() REGENXBIO Inc.
RGNX
|
$8.425 | $417.42M | AAV-based gene therapy platform | AAV Platform Rare Disease |
16 |
![]() Prime Medicine, Inc.
PRME
|
$2.54 | $333.15M | Prime editing technology platform | Prime Editing Platform Research |
17 |
![]() ContextLogic Inc.
LOGC
|
$7.84 | $206.08M | Gene editing for CAR-T therapy | CAR-T Platform Oncology |
18 |
![]() Solid Biosciences Inc.
SLDB
|
$3.0791 | $123.02M | Gene therapy for rare diseases | AAV Rare Disease Muscle |
19 |
![]() Talaris Therapeutics, Inc.
TALS
|
$2.72 | $116.44M | Base editing for genetic diseases | Base Editing Platform Research |
20 |
![]() Editas Medicine, Inc.
EDIT
|
$1.27 | $104.84M | CRISPR ocular and oncology programs | CRISPR Ocular Oncology |
21 |
![]() bluebird bio, Inc.
BLUE
|
$6.4635 | $62.84M | Lentiviral gene therapy platform | Lentiviral Blood Rare Disease |
22 |
![]() Precision BioSciences, Inc.
DTIL
|
$4.98 | $39.30M | ARCUS gene editing platform | ARCUS Platform Research |
23 |
![]() Homology Medicines, Inc.
FIXX
|
$0.9347 | $3.02M | AAV gene therapy technology | AAV CNS Platform |
24 |
![]() Applied Genetic Technologies Corporation
AGTC
|
$0.3936 | $- | AAV gene therapy for eye diseases | AAV Ocular Rare Disease |
VRTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Vertex Pharmaceuticals Incorporated
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

ATTENTION Intellia Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

Mercado Libre CEO and Founder Marcos Galperin Reflects on the company's 25-Year Journey and DNA in Latest Episode of Inside Mercado Libre
Montevideo, Uruguay, 6 February 2025, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mercado Libre (NASDAQ: MELI), the leading e-commerce and fintech platform in Latin America, drops the fifth episode of its podcast series, Inside Mercado Libre, "Marcos Galperin on MELI's Culture” featuring its CEO and founder Marcos Galperin. The Inside Mercado Libre podcast, hosted by Investor Relations Officer, Richard Cathcart, provides investors with unique access to the company executives' strategic views.

Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series
Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters.

ATTENTION VRTX SHAREHOLDERS: Investors who Lost Money on Vertex Pharmaceuticals Incorporated are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Did Intellia Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- NTLA
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni.

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized treatment centers for Casgevy and advancing multiple drug candidates in hemoglobinopathies, CAR-T, and in vivo programs.

Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio.

An Investigation Has Commenced on Behalf of Vertex Pharmaceuticals Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your VRTX Losses.
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Intellia Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- NTLA
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2025, it awarded an inducement grant to three new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

VRTX STOCK ALERT: Levi & Korsinsky Notifies Vertex Pharmaceuticals Incorporated Investors of an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Lost Money on Intellia Therapeutics, Inc.(NTLA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals (VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to eight new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

NTLA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Intellia Therapeutics, Inc. investment
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (VRTX 5.31%) are down about 9% from a peak the stock set in November, despite some highly positive news.

Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential. Phase 2 LSR trial showed minimal benefit vs placebo, raising concerns about $11B peak sales estimates and success in ongoing diabetic neuropathy trial (completion in 2027). Conservative market expectations: Acute pain market $10-20B; $1.5B sales (10% share) more realistic. Must compete with established generics in neuropathic pain market.

Intellia Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- NTLA
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLA
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine
Expectation is a decline in Vertex's earnings, but double-digit revenue growth should continue with the newly approved non-opioid drug JOURNAVX and CF franchise expansion. JOURNAVX, the first non-opioid oral pain signal inhibitor approved in over 20 years, targets a large market, potentially boosting Vertex's revenue significantly over time. The company's CF franchise continues to expand with new approvals and treatments, including TRIKAFTA, ALYFTREK, and VX-522, targeting a broader patient base.

Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
JOURNAVX, a non-opioid analgesic, shows significant promise in treating pain with a superior safety profile, addressing a critical unmet need compared to opioids with FDA approval just announced. Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside.

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Verve Therapeutics, Inc. (NASDAQ: VERV) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive
CNBC's Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new alternative for pain relief that comes without the risk of addiction, concerns around drug effectiveness and costs, and more.

Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. It means that eligible SCD patients in England now have access to the therapy follo.

FDA Approves Non-Opioid Painkiller With No Addiction Risk
The Food and Drug Administration approved Vertex Pharmaceuticals' “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered the start of a new class of non-addictive medicines.

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. “Today's approval is a histori.

Frequently Asked Questions
- CRISPR-Cas9 - Precision DNA editing
- Base Editing - Single base modifications
- Prime Editing - Advanced DNA rewriting
- ZFN - Zinc finger nucleases
- TALEN - Transcription activator-like effectors
- VRTX - Vertex Pharmaceuticals Incorporated
- ALNY - Alnylam Pharmaceuticals, Inc.
- MRNA - Moderna, Inc.
- SRPT - Sarepta Therapeutics, Inc.
- SGFY - Signify Health, Inc.
- Genetic Diseases - Disease correction
- Cancer Therapy - Cell engineering
- Agriculture - Crop improvement
- Rare Diseases - Genetic treatments
- Research Tools - Scientific applications
- Revolutionary technology
- Broad therapeutic potential
- Strong IP protection
- Multiple applications
- Partnership opportunities
- Clinical trial results
- Patent developments
- Technical advances
- Regulatory decisions
- Partnership deals
- Safety profile